Chen-Yen Yang

Chen-Yen Yang

Auto-generated profile, based on publicly available information

Chen-Yen Yang

Division of Hematology and Oncology, Department of Medicine, and

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
CWChi-Heng Wu
Chi-Heng Wu
LWLinlin Wang
Linlin Wang
CYChen-Yen Yang
Chen-Yen Yang
KWKwun Wah Wen
Kwun Wah Wen
BHBrian R Hinds
Brian R Hinds
Weiyun Z. AiWeiyun Z. Ai
Weiyun Z. Ai
CD70 is a member of the tumor necrosis factor receptor superfamily. Emerging data indicate that CD70 may be a suitable target for various malignancies. We investigated the expression of CD70 in cutaneous and systemic T-cell lymphomas and conducted preclinical studies of SGN-CD70A, a CD70-directed antibody-drug conjugate (ADC), using patient-derived xenograft cutaneous T-cell lymphoma (CTCL PDX) models. CD70 expression was examined by immunohistochemical (IHC) stains in 49 diagnostic specimens of T-cell lymphomas. The activities of SGN-CD70A in growth inhibition and apoptosis induction were examined in CTCL cell lines and primary CTCL tumor cells. Using previously established CTCL PDXs, we conducted a dose-finding trial followed by a phase 2-like trial to evaluate the optimal dosing and the efficacy of SGN-CD70A in tumor-bearing PDX animals. The therapeutic efficacy of SGN-CD70A was measured by tumor-associated cell-free DNA (cfDNA) and survival of treated PDXs. We found that CD70 is highly expressed in T-cell lymphomas, especially in CTCL. SGN-CD70A inhibited cell growth and induced apoptosis in CD70-expressing CTCL cell lines and primary tumors cells. Additionally, SGN-CD70A at 100 μg/kg and 300 μg/kg prolonged the survival of PDXs in a dose-dependent manner. Finally, treatment with 3 doses of SGN-CD70A at 300 μg/kg was superior to a single-dose treatment in survival prolongation (median survival: 111 days vs 39 days; P = .017). Most importantly, multiple dosing of SGN-CD70A induced complete eradication of established tumors in PDXs measured by cfDNA. Our results demonstrated marked antitumor activity of SGN-CD70A in CTCL PDXs, providing compelling support for its clinical investigation.

1 February 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
CWChi-Heng Wu
Chi-Heng Wu
CYChen-Yen Yang
Chen-Yen Yang
LWLinlin Wang
Linlin Wang
HGHua-Xin Gao
Hua-Xin Gao
TRTaha Rakhshandehroo
Taha Rakhshandehroo
Weiyun Z. AiWeiyun Z. Ai
Weiyun Z. Ai